Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab

Ekaterina Mikhailova; Evgeny Gluhanyuk; Olga Illarionova; Elena Zerkalenkova; Svetlana Kashpor; Natalia Miakova; Yulia Diakonova; Yulia Olshanskaya; Larisa Shelikhova; Galina Novichkova; Michael Maschan; Alexey Maschan; Alexander Popov

doi:10.3324/haematol.2019.241596

Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab

Haematologica. 2021 Jul 1;106(7):2009-2012. doi: 10.3324/haematol.2019.241596.

Affiliation

¹ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; 1 Samory Mashela St., Moscow 117998, Russian Federation.

Abstract

Not available.

Publication types

Letter

MeSH terms

Antibodies, Bispecific* / therapeutic use
Antineoplastic Agents* / therapeutic use
B-Lymphocytes
Child
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Antibodies, Bispecific
Antineoplastic Agents
blinatumomab

Grants and funding

Funding: the KMT2A rearrangement assessment study was supported by RFBR grant n. 17-29-06052 and Presidential grant n. MK-1645.2020.7 (n. 075-15-2020-338)